Last updated: 11/07/2018 07:17:10
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohn's DiseaseSHIELD-1
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohn's Disease
Trial description: This is a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A as compared to placebo over 12 weeks in adult subjects with moderately-to-severely active Crohn’s disease. Efficacy will be assessed by proportion of subjects achieving response, defined as a decrease in Crohn’s Disease Activity Index (CDAI) score of at least 100 points (clinical response). Clinical remission (CDAI score less than 150 points) will be evaluated as a key secondary endpoint. Safety will be assessed by recording of adverse events, clinical laboratory parameters, vital signs and electrocardiogram (ECG). Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 version 2 (SF-36v2), EQ-5D and Work Productivity and Activity Impairment-CD (WPAI-CD) and receipt of disability.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Percentage of participants with Crohn’s Disease Activity Index (CDAI) response at Week 12
Timeframe: Week 12
Secondary outcomes:
Percentage of participants with CDAI Remission at Week 12
Timeframe: Week 12
Percentage of participants with a clinical response (CDAI decrease from baseline of >= 100 points) at both Week 8 and Week 12
Timeframe: At Week 8 and 12
Percentage of participants achieving clinical remission (CDAI <150 points) at both Week 8 and Week 12
Timeframe: Week 8 and 12
Percentage of Participants with a clinical response (CDAI decrease from baseline of >=100 points) at Week 8
Timeframe: Week 8
Percentage of participant achieving clinical remission (CDAI <150 points) at Week 8
Timeframe: Week 8
Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at both Weeks 8 and 12
Timeframe: Baseline (Week 0), Week 8 and Week 12
Incidence of adverse events (AE) and serious adverse events (SAE)
Timeframe: Up to Week 12
Interventions:
Enrollment:
608
Primary completion date:
2013-11-07
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
B. G. Feagan, W. Sandborn, G. D’Haens, S. Lee, M. Allez, R. Fedorak, U. Seidler, S. Vermeire, I. Lawrance, A. Maroney, C. H. Jurgensen, A. Heath, D. J. Chang.Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.Aliment Pharmacol Ther.2015;42(10):1170–1181.
Medical condition
Crohn's Disease
Product
vercirnon
Collaborators
Not applicable
Study date(s)
December 2010 to July 2013
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Male or female subjects aged 18 years or older
- Written informed consent
- If female: pregnant, has a positive pregnancy test or is breast-feeding
- Diagnosis of coeliac disease, follow a gluten-free diet to manage symptoms, or positive test for coeliac disease
Inclusion and exclusion criteria
Inclusion criteria:
- Male or female subjects aged 18 years or older -Written informed consent -Diagnosis of Crohn’s disease for greater than 4 months duration with small bowel and/or colonic involvement -Confirmation of Crohn’s disease established by visualisation of the gastrointestinal tract within the 12 months prior to screening or by screening endoscopy at study entry -History of inadequate response and/or intolerance/adverse event leading to discontinuation of either corticosteroids or immunosuppressants -Moderately-to-severely active disease characterised by a CDAI score between 220 and 450, inclusive, at Baseline -Confirmation of current active Crohn’s disease by screening endoscopy or inflammatory biomarkers [elevated C-reactive protein (greater than upper limit of normal) plus positive test for faecal calprotectin] at Screening -Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn’s disease -Demonstrated ability to comply with Crohn’s disease symptom recording using the interactive voice response system -Females of child-bearing potential must be sexually inactive or commit to consistent and correct use of a contraceptive method of birth control with a failure rate of less than 1% for the duration of this study
Exclusion criteria:
- If female: pregnant, has a positive pregnancy test or is breast-feeding -Diagnosis of coeliac disease, follow a gluten-free diet to manage symptoms, or positive test for coeliac disease -Diagnosis of ulcerative or indeterminate colitis -Enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period -Bowel surgery, other than appendectomy, within 12 weeks prior to screen and/or has surgery planned or deemed likely for Crohn's disease during the study period -Extensive colonic resection, subtotal or total colectomy -Presence of ileostomies, colostomies or rectal pouches -Known fixed symptomatic stenoses -History of more than 3 small bowel resections or diagnosis of short bowel syndrome -Chronic use of narcotics for chronic pain defined as daily use of one or more doses of narcotic containing medication -Use of prohibited medications, including enteral feeding or elemental diet, within their specified time frames a. Biologic use: Use of any biologic (tumour necrosis factor inhibitor or natalizumab) within 8 weeks prior to screening b. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to screening c. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks prior to screening d. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn’s disease within 4 weeks prior to screening e. Use of rectal treatment with 5-ASA or corticosteroid enemas/suppositories within 2 weeks prior to screening f. Use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening g. Leukocytapheresis or granulocytapheresis within 2 weeks prior to screening -Positive immunoassay for Clostridium difficile -Known human immunodeficiency virus (HIV) infection -Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening -Immunisation with a live vaccine within 4 weeks of screening, with the exception of influenza vaccine -Active or latent tuberculosis infection -Current sepsis or infections requiring intravenous antibiotic therapy for more than 2 weeks -Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of liver disease including non-alcoholic steatohepatitis (NASH) -Positive test for Hepatitis B or Hepatitis C antibody at screening -Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450 milliseconds -Concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study -History or evidence of adenomatous colonic polyps that have not been removed -History of evidence of colonic mucosal dysplasia -Current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or any cancer in situ that has been resected) -Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx compound CCX282-B) -Medical history of sensitivity to any of the components of GSK1605786A -Use of any investigational product within 30 days prior to screening
Trial location(s)
Location
GSK Investigational Site
Tupelo, Mississippi, United States, 38801
Status
Study Complete
Showing 1 - 6 of 216 Results
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2013-11-07
Actual study completion date
2013-11-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website